Investment year


Mylan is a global pharmaceutical company committed to implementing new and better ways to help people around the world to achieve a better quality of life. Their work sets new standards in health care and provides 7 billion people with access to high-quality medications.

Mylan produces both generic and specialty drugs, and is also one of the world’s largest manufacturers of active pharmaceutical ingredients (the ingredients that are responsible for the efficacy of the drug). The company’s specialty drugs include prescription drugs for respiratory diseases, life-threatening reactions and psychiatric disorders.

Head office: Göteborg
CEO: Peter Zachrisson
Chair of the Board: Martin Svalstedt
Sales: 221 MSEK
Employees: 12
Stena Adactum’s holdings: 100 %
Investment year: 2005
Investment responsibility: Martin Svalstedt
Website : stenarenewable.se

Northern America 40.4
Europe 32.7
Rest of world 26.9